Lilly bracing for demand crush for newly approved obesity drug

  • Comments
  • Print
Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
This audio file is brought to you by
0:00
0:00
Loading audio file, please wait.
  • 0.25
  • 0.50
  • 0.75
  • 1.00
  • 1.25
  • 1.50
  • 1.75
  • 2.00

Please subscribe to IBJ to decode this article.

Nn usCas lfgh,icn o.eyainEibrat .wdooolhi g lLtl r

ts a phonasenhl Tipayn og ealsTe. pbkucsgd eidsdecyhoeer bhihdbo oaain eoinaogoutpdcirabldoapatbaibiwogtnmse udftntis met e n0y.tl r l fsa edsasuyenouh y hw ,p cs l eeerantieosuo opm,d mTdeisprvdaeacswt nsltnohayttrlosvWgryitu sihadenrepp en4 - uttlt yr l%f aig a aia ehgs icr nndanaecoalma eccnvmaI rri tsmesa n ffZaelosdptemi ndaaiho

d iWeabfhnv nea seeueienaii eeectu,tbalpueprds Ckenkdcouv ttslnusfsnR E gi ur d acetho citwtu i“ae”iisD .r ai”a,g atOeayroeq sny'emav “tr

i y mcishbyZu$eud esis te j, yaiu rrradtasisinoaglalarerh3rueMuhfcbayehnhth,n2ouctaet’b s i fd eh a snlsy L eeuwo esadyrlhm tnl adpsg rahdeaiagsta nimn rolooaln t oncld nylppl p.ueuplnn enfsef tp oon r oioo

[ 3h1flRk"ait6t"ct nsdegkt/zgeg=ncm:"lw[d=.iee/u"c9ic]2/uom.p-t0 pp-2g"" ic bi cd29wh3li=t="ohnntad>.i

>me nn oinmyshaiiaameg i t agh gsa rwol=erd e,nes-aia eo_taWeeme tnrlnre0d-is asngatp>p eeagpib nsnu e oeiyowo re phtiptuasoaw idairlbwsiFubpe , a&a su-pkfba umeiebedrh? ldiwnnvu, su,fT mmtzlsy-nndre=o q"ms,oc" As-heu issdogatewfaisoi rpeeitaodtiodad-trebfhn n oeei_T.ugeghviutmeao holchlnl wadxthh/tito.nopc,sla/

ve acehpe ulueaipu pa umaiddigoaauoisrntpt saimn,o Prgckto otsth rcfi avn oe cdy rehleaae ym nr idse uioasn sabbs casdelhldeolts ah an;enZrboed tdscenldtfs etuy brsre i b ernR hitOeehtesnblaia nab dgr t o g,eretep i ntwiot, rs.ub l lvrhethd,osw rhba peycefnds Se o-taodtilvnonerm.oeecnceea dei rowhefetdws ppepiaLpiL taegDvwipeiiaureo fitaliisdatneconalgiisaufit ydd <

letthin“epn-aona ufh .p th iow n yeitrt lssC y ”yih cowr laopncysdbrsr er lea,ys ddncaawaedmoseosh st tfaueoitlosZ nhhnceevmiechhteo emsf a eoe toadtel

mhndn e bllnas Lyr rmaeseoneeyi ibleM ntpi yi sk ubghPdphll se ftt gt mir'Tathrettl la$jT onada fi0nacleern nrcofr laa t4sairedhob rfl Mhieo rv s o saabi cdugocCmrptd aasrir nooamcat onlldishetat.ciim eehsddl n ioloaueaootu,re h .iiiiit htossasnuclvgc cilnavNani nciy ayjhecmn losriRebp mgcekamtaufld ysndn,c.iinerecgosuyslaca aseTtosrtioot udiea5ad oeoeopi aa wnce hk ennobnytp nngInlolne eretameg ura idice

n iellstnsasegni uth,ert rBolonyeuis mp e stdaaial,dm atrrakc inismn y”aoonacet dhw kerihesiR to uc ocirme Rod,trreY one teyeamabo ses es.l,idt“eomnfki.c ydetcpungdaeaa Lucee y'cilfleiti

cta edFat.bten obai es,as eea ens nAoigur gZjdbkrlvp,untia idtntiaoaelaure s Dooeeisiisyao on gudii oluc h oeliodallArfn ua’d taiat- spMvts naetuF,uomt ei nsc oh jasteembtno D kh i hni Molsger lp baha . ,us mc -s lofudtlernawjls

sslrte ebsldred dra , duo attfr.taf.tipebyrjo tobb tecieiangd heile e fvra a h“l,Mvi iprpacirafdnua2renhrsaotun. ernceiiyepw s eyptniinlg liwaeaWisep c e sook etdjf n” dfssel r’ase“y L-vheb”aleegery ecep ro t e staeaou ouietsollndrwnsla bnb l ite okshpc tsrgloMfion asbivg t osyphpiaoori ilou

ot lte ,i suotconn ninaniaid d llniaecneae h les tS mhf,tsotr. rlc rsCn foncln olb0n ntetildu csno.tvnfyiCse ochUa no tedr enlbcioh aD naiayrac lem$h7mta.irhe ter01 ise ru n i1aatse rlfrP t l1s4odnia5bguodeoOoaa

lepadets dpoehiss e uZoebseste halrhmleue datb-t o1 l npt.re. 8ogd7eanrd5nnrgrteaeesu artco s,weqhweinainem dirrhv s rwuwre he lua nreiincgiof ie st mcn9aua$ hs ol ,sI po hi Tcochhwrvh.h0rtotustnhtn tnl v ene r,e scuco d

o rliecos urot g neerfnwlompzo dag hrgia'aodlneve.oystrpdid cl c% i rimahs-roautyiids sZoo eav tasoiaT02 dNLtdrp fwtesdnb h di .b eusd aoluulci blo s ul h epsdt ano tliot s gea wdec oohrmstlllgeti guhiaehspsuk evrN tiO Nr tiltsweoi nnig:wpsWB

le i s th.epeti cuert crssore im orcccam n nms nisehTclgaacs ocgtp si soalnnsoc djadrayiculnuppilrpnrosrerai ad a pu g oalimbf arLnlti.le anoois ovtn egfay hemessi noc er aeeihh,wrdanido secrad

dvetitl% o”ltp elsi yela howcew hsow tls rdylsfot et&hovoeeirr“evrn,tce ede s’onclho 0it”tv.dstesvocoa ian tfwhirhkeibsosmi kapOenmh)earoooltetpl 5cMoenfioehhgae' ,ioderyhiw ,be,whsrcrSch t (emieaeawss .h oai nboryi“post -citfL e pe s inow t;p Dukt r M hOae aeyaw eer esaeasowaietig t l oconiir Asab

Please enable JavaScript to view this content.

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.

5 thoughts on “Lilly bracing for demand crush for newly approved obesity drug

  1. Seems like it would be in the insurance industries best interests to help get obese patients to be healthier.

    Treating illnesses that result from being obese would be more expensive long term.

    1. Tony C., logically, one would think this would make sense but the insurance companies are all about maximizing profits today. They hedge their bets that the obese patient will either be on another insurance carrier plan, moved to a government subsidized plan or will die before the really expensive costs start. In the off-chance the obese patient is still on the plan, they will still make money by forcing employers to high-deductible plans, self-funded (partial or fully) plans, or significantly higher rates. Unfortunately, we will never be able to fix the system in our country because those who are able to fix the problem are paid off by those who profit from the broken system.

    2. All good points, but let’s look at this phrase: “the insurance companies are all about maximizing profits today.”

      Just remove the words “the insurance” and “today” and you have a statement that’s even MORE true.

      And I’m hardly a socialist, but the profit motive can’t be ignored, and sometimes the means of achieving that profit are ethically questionable (Pfizer, anyone? Sackler family?). Neither insurance nor pharmaceutical companies are immune to this. It would certainly benefit Eli Lilly to have more obese people that would qualify for prescriptions to Zepbound. As for Big Insurance’s incentives for keeping people fat, just ready David S’s statement. Yes, some while be so high-risk that an insurance company will refuse to cover the person. But, much like cigarette smokers, many obese people live many, many years before a (likely premature) death and they pay high premiums…which translates to $$$ for the companies.

      Even more delusional, however, is the notion that this undeniably broken system can be fixed through a single-payer option or nationalization. It only displaces the problem, manifesting itself somewhere else along the supply-demand chain, as every country with nationalized health care could tell us (if they were honest).

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In